Nitrogen Containing Patents (Class 514/471)
-
Patent number: 8808742Abstract: This invention relates to compositions, methods for preparing the compositions and methods for treating or preventing diseases, comprising administering the compositions.Type: GrantFiled: April 14, 2009Date of Patent: August 19, 2014Assignee: Ardea Biosciences, Inc.Inventors: Barry D. Quart, Colin Edward Rowlings
-
Publication number: 20140221286Abstract: It is discovered that sodium-channel blockers inhibit the secretion of glucagon from pancreatic alpha cells. The present disclosure, based on such discoveries, provides compositions and methods for the treatment of hyperglycemia and related diseases and conditions with Na-channel blockers.Type: ApplicationFiled: September 20, 2012Publication date: August 7, 2014Inventors: Luiz Belardinelli, Arvinder Dhalla
-
Publication number: 20140221363Abstract: The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof, and at least one kind of neonicotinoid compounds selected from the group (A) consisting of imidacloprid, clothianidin, thiamethoxiam, dinotefuran, acetamiprid, thiacloprid and nitenpyram, shows an excellent controlling efficacy on harmful arthropods.Type: ApplicationFiled: July 20, 2012Publication date: August 7, 2014Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi Iwata, Chie Shimizu, Miki Suzuki
-
Publication number: 20140221284Abstract: The invention provides compositions and methods for determining GLP-1 analog and/or DPPIV inhibitor response in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, C-peptide, hsCRP, insulin, proinsulin. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in characterizing GLP-1 analog and DPPIV inhibitor response. The invention also provides methods of treating a subject (e.g. one experiencing cardiodiabetes) and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.Type: ApplicationFiled: January 23, 2012Publication date: August 7, 2014Applicant: IR2DX, Inc.Inventor: Andreas Pfuetzner
-
Patent number: 8796303Abstract: The present invention relates to compounds of formula (I), racemates, isomers and/or salts thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds.Type: GrantFiled: November 22, 2011Date of Patent: August 5, 2014Assignee: Biota Scientific Management Pty Ltd.Inventors: Penelope Anne Mayes, Jeffrey Peter Mitchell, Alistair George Draffan, Gary Robert William Pitt, Kelly Helen Anderson, Chin Yu Lim
-
Patent number: 8796176Abstract: PROBLEM Provided is a composition for controlling pests having excellent control effect for pests and a method for controlling pests. SOLUTION A composition for controlling pests comprising an ?-alkoxyphenylacetic acid compound and a neonicotinoid compound as active ingredients.Type: GrantFiled: September 17, 2009Date of Patent: August 5, 2014Assignee: Sumitomo Chemical Company, LtdInventors: Masanao Takaishi, Atsushi Iwata
-
Publication number: 20140213594Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: ApplicationFiled: April 1, 2014Publication date: July 31, 2014Applicant: NOVARTIS AGInventors: Urs BAETTIG, Anne-Marie D'SOUZA, Peter HUNT, Neil John PRESS, Simon James WATSON
-
Patent number: 8791102Abstract: This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particular, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.Type: GrantFiled: October 16, 2009Date of Patent: July 29, 2014Assignee: Exelixis, Inc.Inventors: Mohamed Abdulkader Ibrahim, Joon Won Jeong, Henry William Beecroft Johnson, Patrick Kearney, James W. Leahy, Gary L. Lewis, Robin Tammie Noguchi, John M. Nuss
-
Publication number: 20140206769Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.Type: ApplicationFiled: January 17, 2014Publication date: July 24, 2014Applicant: CARDIOXYL PHARMACEUTICALS, INC.Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
-
Publication number: 20140206651Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.Type: ApplicationFiled: March 24, 2014Publication date: July 24, 2014Applicant: Pfizer Inc.Inventors: Matthew Frank Brown, Charles Francis Donovan, Edmund Lee Ellsworth, Denton Wade Hoyer, Timothy Allan Johnson, Manjinder Singh Lall, Chris Limberakis, Sean Timothy Murphy, Debra Ann Sherry, Clarke Bentley Taylor, Joseph Scott Warmus
-
Patent number: 8785662Abstract: The present invention relates to a preservative for preserving wood comprising 5-methyl-2-trifluoromethylfuran-3-carboxylic acid anilide derivative represented by the following formula, wherein R represents an iropropyl group or an isopropoxy group as an active ingredient. The preservative for preserving wood has an excellent preservative effect on various wood-decay fungi at an extremely low dose, is economically efficient, and imposes a small burden on the environment. The present invention also relates to a method for treating wood using the preservative.Type: GrantFiled: May 12, 2010Date of Patent: July 22, 2014Assignee: SDS Biotech K.K.Inventors: Keijitsu Tanaka, Masahiro Maesawa
-
Patent number: 8785451Abstract: Disclosed are compounds of formula (IA), formula (IV) or formula (V), wherein the variables are as defined herein, and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.Type: GrantFiled: August 20, 2007Date of Patent: July 22, 2014Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Jun Jiang
-
Publication number: 20140187541Abstract: The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising a carboxylic acid compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at least one kind of neonicotinoid compounds selected from the group (A) consisting of imidacloprid, clothianidin, thiamethoxiam, dinotefuran, acetamiprid, thiacloprid and nitenpyram, shows an excellent controlling efficacy on harmful arthropods.Type: ApplicationFiled: July 20, 2012Publication date: July 3, 2014Inventors: Atsushi Iwata, Chie Shimizu, MIki Suzuki
-
Publication number: 20140179681Abstract: Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.Type: ApplicationFiled: January 8, 2014Publication date: June 26, 2014Inventor: Joseph P. Errico
-
Publication number: 20140179692Abstract: The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at least one kind of neonicotinoid compounds selected from the group (A) consisting of imidacloprid, clothianidin, thiamethoxiam, dinotefuran, acetamiprid, thiacloprid and nitenpyram, shows an excellent controlling efficacy on harmful arthropods.Type: ApplicationFiled: July 20, 2012Publication date: June 26, 2014Applicant: SUMITOMO CHEMICALCOMPANY, LIMITEDInventors: Atsushi Iwata, Chie Shimizu, Miki Suzuki
-
Patent number: 8759379Abstract: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.Type: GrantFiled: December 19, 2008Date of Patent: June 24, 2014Assignee: Gilead Sciences, Inc.Inventors: Manoj C. Desai, Hon C. Hui, Hongtao Liu, Lianhong Xu
-
Publication number: 20140170215Abstract: A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.Type: ApplicationFiled: August 23, 2013Publication date: June 19, 2014Inventors: Gopi M. VENKATESH, Ken Kangyi Qian, Shyam Vangala, James M. Clevenger, Donald Guenther
-
Publication number: 20140171426Abstract: The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising an amide compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at least one kind of neonicotinoid compounds selected from the group (A) consisting of imidacloprid, clothianidin, thiamethoxiam, dinotefuran, acetamiprid, thiacloprid and nitenpyram, shows an excellent controlling efficacy on harmful arthropods.Type: ApplicationFiled: July 20, 2012Publication date: June 19, 2014Inventors: Atsushi Iwata, Chie Shimizu, Miki Suzuki
-
Patent number: 8748412Abstract: Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metabolic disorder.Type: GrantFiled: February 2, 2011Date of Patent: June 10, 2014Assignee: Argusina Bioscience Inc.Inventors: Jiayu Liao, Yufeng Hong, Yong Wang, Thomas W. Von Geldern, Kanyin E. Zhang
-
Publication number: 20140155420Abstract: The invention provides small molecule inhibitors of EYA2 phosphatase activity and EYA2 binding to Six1. These inhibitors are proposed for use in methods of treating cancer in a subject, such as those involving Six1 and/or EYA2 disregulation. In some embodiments, the invention further provides for the administration of a second cancer therapy to the subject.Type: ApplicationFiled: January 10, 2012Publication date: June 5, 2014Applicants: The Regents of the University of Colorado, a body corporate, Department of Health and Human ServicesInventors: Rui Zhao, Heide L. Ford, Noel Southall, Erika Englund, Samarjit Patnaik, Marc Ferrer, Wei Zheng, Seameen Dehdashti, Juan Marugan
-
Publication number: 20140154323Abstract: Administration of a loop diuretic in nebulized dry powder form directly to a patient's lungs for treating bronchial disease.Type: ApplicationFiled: February 6, 2014Publication date: June 5, 2014Applicant: MICRODOSE THERAPEUTX, INC.Inventor: Andrew Abrams
-
Publication number: 20140141087Abstract: The invention provides an oral composition comprising a pharmaceutically acceptable carrier, at least one antacid, an inorganic matrix comprising at least silicon dioxide and titanium dioxide, and an anaesthetic, wherein the composition is substantially evenly dispersed in the carrier and is palatable.Type: ApplicationFiled: July 13, 2012Publication date: May 22, 2014Applicant: Eupharma Pty LtdInventor: Malvin Eutick
-
Publication number: 20140142156Abstract: Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial.Type: ApplicationFiled: December 12, 2013Publication date: May 22, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Helen E. BLACKWELL, Christine E. McINNIS
-
Publication number: 20140135321Abstract: Described herein are compounds, compositions, and methods for treating HIV and related diseases.Type: ApplicationFiled: January 16, 2014Publication date: May 15, 2014Inventor: Arun K. GHOSH
-
Publication number: 20140135389Abstract: The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogenesis.Type: ApplicationFiled: January 22, 2014Publication date: May 15, 2014Inventors: Gael RONSIN, Laura STORONI, Francesca BENEDINI
-
Patent number: 8722730Abstract: A compound represented by the following general formula (I): [wherein R1 and R2 represent an alkyl group, X represents —S—, —O— or —NH—, Y represents C or N, R3 represents hydrogen atom or a C1-10 alkyl group, Z represents —CO—N(R5)— (R5 represents hydrogen atom or a C1-6 alkyl group) or —C(R6)?C(R7)—CO—NH— (R6 and R7 represent hydrogen atom or a C1-6 alkyl group), Ar represents an aryldiyl group or a heteroaryldiyl group, and R4 represents —COOH, —OCH2—COOH, —CH2—COOH, or —CH2—CH2—COOH], which has a retinoid action and is useful as an active ingredient of a medicament.Type: GrantFiled: August 14, 2008Date of Patent: May 13, 2014Assignee: Research Foundation Itsuu LaboratoryInventors: Hideaki Muratake, Masayuki Noguchi, Koichi Shudo
-
Patent number: 8722731Abstract: Provided herein are substituted furanyl compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate eIF4E activity. In one embodiment, the compounds provided herein modulate the Hedgehog pathway activity. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.Type: GrantFiled: June 7, 2011Date of Patent: May 13, 2014Assignee: NovoMedix, LLCInventors: Leah M. Fung, Kyle W. H. Chan, Cathy A. Swindlehurst
-
Publication number: 20140128427Abstract: Provided are a novel derivative of 5-carbamoyl adamantan-2-yl amide or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof for inhibiting the activity of 11?-hydroxystreroid dehydrogenase type 1 (11b-HSD1) or for preventing and/or treating various diseases mediated by 11?-hydroxystreroid dehydrogenase type 1.Type: ApplicationFiled: June 11, 2012Publication date: May 8, 2014Applicant: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Coo-Min Chung, Choon-Ho Ryu, Yoon-Kyeong Lee, Jin-Sook Moon, Hye-Sung Lee, Seon-Jeong Lee, Kyung-Seok Oh
-
Publication number: 20140107161Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R2, R3, R4, G1, n, A1, A2, A3, A4, Y1, Y2, and Y3 are as defined in the claims. The invention also relates to processes and intermediates for preparing these compounds, to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising these compounds and to methods of using these compounds to control insect, acarine, nematode and mollusc pests.Type: ApplicationFiled: May 12, 2012Publication date: April 17, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Jerome Yves Cassayre, Myriem El Qacemi, Torsten Luksch, Peter Renold
-
Patent number: 8691780Abstract: Methods and compositions for enhancing taxane sensitivity are provided. Aspects of the subject methods include administering to a subject a txr1 pathway modulatory agent in conjunction with a taxane. Also provided are txr1 polypeptides and nucleic acids encoding the same. The subject methods and compositions find use in a variety of different applications.Type: GrantFiled: February 16, 2006Date of Patent: April 8, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chih Jian Lih, Stanley N. Cohen
-
Publication number: 20140094492Abstract: Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.Type: ApplicationFiled: March 30, 2012Publication date: April 3, 2014Applicant: Southern Research InstituteInventors: Robert Reynolds, Bini Mathew, Gary A. Piazza
-
Publication number: 20140094455Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.Type: ApplicationFiled: August 19, 2013Publication date: April 3, 2014Applicant: ARIZONA BOARD OF REAGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter
-
Publication number: 20140094457Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mRNA) susceptible to nonsense mediated RNA decay, in a subject. Also disclosed is a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy. The present invention also relates to a method of identifying inhibitors of nonsense mediated RNA decay and/or inducing autophagy. The present invention further relates to a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy in a subject.Type: ApplicationFiled: October 2, 2013Publication date: April 3, 2014Applicant: NEW YORK UNIVERSITYInventors: Lawrence B. Gardner, Timothy J. Cardozo, Leenus Martin
-
Publication number: 20140094489Abstract: The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I) wherein each symbol is as described in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 6, 2013Publication date: April 3, 2014Applicant: AJINOMOTO CO., INC.Inventors: Tamotsu SUZUKI, Takahiro KOSHIBA, Munetaka TOKUMASU, Koji OHSUMI
-
Patent number: 8686027Abstract: Administration of a loop diuretic in nebulized dry powder form directly to a patient's lungs for treating bronchial disease.Type: GrantFiled: December 7, 2011Date of Patent: April 1, 2014Assignee: Microdose Therapeutx, Inc.Inventor: Andrew Abrams
-
Publication number: 20140086990Abstract: An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having Cmax to Cmin ratio less than 200 and lag time less than 0.2.Type: ApplicationFiled: March 8, 2013Publication date: March 27, 2014Applicant: DURECT CORPORATIONInventor: DURECT CORPORATION
-
Patent number: 8680100Abstract: The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex of a deprotonated form of the compound. Pharmaceutical composition and method of use for these compounds are also included.Type: GrantFiled: December 1, 2009Date of Patent: March 25, 2014Assignee: Synta Pharmaceuticals Corp.Inventors: Jun Jiang, Teresa Kowalczyk-Przewloka, Stefan M. Schweizer, Zhi-Qiang Xia, Shoujun Chen, Christopher Borella, Lijun Sun
-
Publication number: 20140080790Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: ApplicationFiled: November 25, 2013Publication date: March 20, 2014Applicant: AJINOMOTO CO., INC.Inventors: Atsushi KONISHI, Munetaka Tokumasu, Tamotsu Suzuki, Takahiro Koshiba, Koji Ohsumi, Osamu Ikehara, Yuko Kodama
-
Publication number: 20140031398Abstract: Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula: Wherein R is selected from: H, Br, CN, NO2, SO2NH2, SO2NHR? and SO2NR?2, where R? is selected from linear or branched C1-C4 alkyl; X is selected from: F, Cl, C1-C3 alkyl, NH2 and OH Y is selected from: O, CH2, NH and SO2 R1 and R2, independently one from the other, are selected from H, F and linear or branched C1-C4 alkyl; R3 and R4, independently one from the other, are selected from H and linear or branched C1-C4 alkyl; Z is selected from: NR6 and R6R7N+, where R6 and R7 independently one from the other, are selected from: H and linear or branched C1-C4 alkyl R5 is a residue selected from: H and linear or branched C1-C4 alkyl Het is a heteroaryl group selected from a substituted or not substituted pyrrolyl, a substituted or not substituted N-methylpyrrolyl, a substituted or not substituted thiophenyl, a substituted orType: ApplicationFiled: January 27, 2012Publication date: January 30, 2014Inventors: Alessio Moriconi, Gianluca Bianchini, Andrea Aramini, Laura Brandolini, Chiara Liberati, Silvia Bovolenta, Andrea Beccari, Simone Lorenzi
-
Publication number: 20140031290Abstract: Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analyses of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or prophylactic use, and methods of use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor of such compounds are provided.Type: ApplicationFiled: July 8, 2013Publication date: January 30, 2014Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Liming Huang, Junko Tamiya, Mark T. Griffith, Thomas Fowler, Andrew Novak, Michael Knaggs, Premji Meghani
-
Patent number: 8623859Abstract: The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: GrantFiled: August 10, 2009Date of Patent: January 7, 2014Assignee: Evotec AGInventors: James Madden, David James Hallett, Alastair Parkes, Ali Raoof, Xiaolu Wang
-
Publication number: 20140005235Abstract: The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein A1, A2, A3, A4, A5, A6, G1, G2, R1, R2, R3, L, Q1, Q2, R4, R5, R6, R7, Q2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, and Y9 are as defined in claim 1; or salts or N-oxides thereof.Type: ApplicationFiled: March 19, 2012Publication date: January 2, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Pierre Joseph, Marcel Jung, Ottmar Franz Hueter, Peter Renold, Thomas Pitterna
-
Publication number: 20130337022Abstract: A pH responsive and mucoadhesive pharmaceutical dosage form for the release of a pharmaceutically active agent is described. The dosage form includes a mucoadhesive layer for site-specific mucoadhesion, a water-insoluble outer layer, and an intermediate layer including one or more pharmaceutically active agents for site-specific delivery. The different membranous layers perform different functions in order to create a drug delivery system which is able to deliver a drug to a specific site, for a particular period of time and with a specific drug release pattern. The dosage form can have two or more intermediate layers, each layer comprising an active agent. The mucoadhesive layer can also include an active agents. The dosage form is preferably an oral or buccal delivery form for release of the active agent into the gastro intestinal tract. The intermediate layer can be an electrospun fibrous membrane layer containing the active agent.Type: ApplicationFiled: November 28, 2011Publication date: December 19, 2013Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Viness Pillay, Rubina Perveen Shaikh, Yahya Essop Choonara, Lisa Claire Du Toit
-
Publication number: 20130331411Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.Type: ApplicationFiled: September 23, 2011Publication date: December 12, 2013Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, THE BROAD INSTITUTE, INC.Inventors: Chris Dockendorff, Robert Flaumenhaft, Lawrence MacPherson
-
Publication number: 20130323179Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.Type: ApplicationFiled: May 3, 2013Publication date: December 5, 2013Applicant: Johns Hopkins University, TheInventors: Alexey Popov, Elizabeth M. Enlow, James Bourassa, Colin R. Gardner, Hongming Chen, Laura M. Ensign, Samuel K. Lai, Tao Yu, Justin Hanes, Ming Yang
-
Publication number: 20130317007Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.Type: ApplicationFiled: April 11, 2013Publication date: November 28, 2013Applicant: Reata Pharmaceuticals, Inc.Inventors: Eric ANDERSON, Xin JIANG, Melean VISNICK
-
Publication number: 20130309324Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.Type: ApplicationFiled: July 26, 2013Publication date: November 21, 2013Applicants: RadioRx, Inc., c/o Interwest Venture Partners, Alliant Techsystems Inc.Inventors: Mark D. Bednarski, Susan Knox, Louis F. Cannizzo, Kristin F. Warner, Robert B. Wardle, Stephen P. Velarde, Shoucheng Ning
-
Publication number: 20130303527Abstract: What are described are novel active compound combinations comprising a known oxime ether derivative (trifloxystrobin) and imidacloprid, which combinations are highly suitable for controlling phytopathogenic fungi and insects.Type: ApplicationFiled: April 11, 2013Publication date: November 14, 2013Inventors: Ulrike WACHENDORFF-NEUMANN, Astrid Mauler-Machnik, Christoph Erdelen, Hirohisa Ohtake
-
Publication number: 20130303549Abstract: Novel biaromatic compounds having the general formula (I): and cosmetic/pharmaceutical compositions comprised thereof are useful in human or veterinary medicine (in dermatology and also in the fields of cardiovascular diseases, of immune diseases and/of diseases related to the metabolism of lipids), or, alternatively, in cosmetic compositions.Type: ApplicationFiled: July 10, 2013Publication date: November 14, 2013Inventors: Jean-Guy BOITEAU, Laurence CLARY, Corinne Millois BARBUIS
-
Publication number: 20130303531Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: May 14, 2012Publication date: November 14, 2013Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris